GLP-1 journey in real time 💉 Honest updates, side effects, news & tips — making healthcare access easier to understand + more human
Live Last read · last published · next check
A Circulation primer pulls together data from over 100,000 people and lands on a genuinely strange conclusion: GLP-1 drugs protect the heart in ways their obvious effects don't account for.
A small Phase 2 trial is testing semaglutide for trichotillomania, betting that GLP-1s quiet the brain's compulsion circuits.
Nearly half of parents starting a GLP-1 said they began offering their children healthier food. It's the first real look at how these drugs reshape a household, not just a body.
A new clinical review covers conception, pregnancy, and postpartum for patients on GLP-1s, a conversation that has been improvised until now.
Researchers pried open the production cost of the world's most famous weight-loss drug, and found the medicine is almost free. It's the plastic pen and the patents that cost you.
A new study shows it is how much your body absorbs, not the dose on the label, that predicts how sick you feel.
A small pilot says a plant-based protein shake fixed the protein gap and eased bloating on GLP-1s. Worth knowing who paid for it, and why the underlying problem matters anyway.
A new review in Biological Psychiatry lays out the preclinical case for GLP-1s against cocaine, meth, and nicotine cravings.
Lilly's response to the "50 pounds vs 33 pounds" lawsuit is in, and it spends a surprising number of pages talking about ads Novo ran.
Novo Nordisk paid its own scientists to test the cheaper competition, found problems, and is waving the results at the FDA. It's real science mixed with propaganda.
A PNAS study identified the enzyme behind GLP-1 muscle loss, and showed that blocking it preserved strength in mice.
